Article

The value of pimecrolimus in improving quality of life of children with severe eczema—an open non-randomised study

Published in: South African Family Practice
Volume 52 , issue 1 , 2010 , pages: 69–71

DOI: 10.1080/20786204.2010.10873939

Author(s): O Kitchin Department of Paediatrics and Child Health, Division of Paediatric Pulmonology, , R Masekela Department of Paediatrics and Child Health, Division of Paediatric Pulmonology, , T Moodley Department of Paediatrics and Child Health, Division of Paediatric Pulmonology, , R Green Department of Paediatrics and Child Health, Division of Paediatric Pulmonology,

Keywords: severe eczema , topical steroids , calcineurin inhibitors , pimecrolimus , quality of life

Download full text Get new issue alerts

Abstract

Background: Atopic eczema is a common skin condition. It has the potential to severely impair quality of life in affected children. Pimecrolimus is currently registered for mild-moderate eczema but in clinical practice children with more severe disease are often treated with this therapy in an attempt to find a safe addition to long-term topical corticosteroid usage. The aim of this study was to test the value of pimecrolimus in improving quality of life in children with severe atopic eczema.

« Breech presentation at a district level hospital in South Africa

A risk-factor profile for chronic lifestyle diseases in three rural Free State towns »